MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Inotek Pharmaceuticals Corp Company Profile (NASDAQ:ITEK)

Consensus Ratings for Inotek Pharmaceuticals Corp (NASDAQ:ITEK) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $32.25 (333.47% upside)

Analysts' Ratings History for Inotek Pharmaceuticals Corp (NASDAQ:ITEK)
Show:
DateFirmActionRatingPrice TargetActions
5/14/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2016Piper JaffrayReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/24/2015NomuraReiterated RatingBuy$13.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/24/2015Cowen and CompanyReiterated RatingOutperform$15.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Inotek Pharmaceuticals Corp (NASDAQ:ITEK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/11/2016Q1($0.22)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/23/2016Q4($0.37)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/15/2015Q115($0.40)($0.21)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Inotek Pharmaceuticals Corp (NASDAQ:ITEK)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Inotek Pharmaceuticals Corp (NASDAQ:ITEK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Inotek Pharmaceuticals Corp (NASDAQ:ITEK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/13/2016J Martin CarrollDirectorBuy10,000$9.03$90,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/23/2015Argeris N KarabelasDirectorBuy603,832$6.00$3,622,992.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/23/2015Park Bioventures Lp DevonMajor ShareholderBuy814,166$6.00$4,884,996.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Inotek Pharmaceuticals Corp (NASDAQ:ITEK)
DateHeadline
06/30/16 07:36 AMWhy Making Dramatic Moves: Inotek Pharmaceuticals Corporation (NASDAQ:ITEK), Navidea Biopharmaceuticals ... - KC Register
06/30/16 07:36 AMWatching Stock Volatility for: Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) - Engelwood Daily
06/30/16 07:36 AMCovering the Bases on Inotek Pharmaceuticals Corporation (NASDAQ:ITEK): Where is the Stock Going? - Press Telegraph
06/29/16 07:31 AMCheck on Share Volatility: Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) - Engelwood Daily
06/27/16 04:27 PMINOTEK PHARMACEUTICALS CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/26/16 04:04 PMInotek Pharmaceuticals Corporation (NASDAQ:ITEK) Went Up 3.26%: Republic Services, Inc. (NYSE:RSG), General ... - KC Register
06/26/16 04:04 PMShare Volatility Check for: Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) - Press Telegraph
06/24/16 07:20 AMInotek Pharmaceuticals Corporation (NASDAQ:ITEK) Earnings Glance and Target Price Review - Engelwood Daily
06/22/16 09:23 AMInotek Pharmaceuticals Corporation (NASDAQ:ITEK) plummeted -6.32%: Maiden Holdings, Ltd. (NASDAQ:MHLD ... - KC Register
06/18/16 09:04 AMStrong Buy Calls Count For Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) At 2 - Investor Newswire
06/16/16 07:39 AMInotek Pharmaceuticals Announces Participation in Fireside Chat at JMP Securities 2016 Life Sciences Conference - [at noodls] - LEXINGTON, Mass.--(BUSINESS WIRE)--Jun. 16, 2016-- Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization ...
06/15/16 03:23 PMBeleaguered Valeant Appoints Lead Independent Director -
06/13/16 04:26 PMTrending Stocks: Vail Resorts (NYSE:MTN), Inotek Pharmaceuticals (NASDAQ:ITEK), Aratana (NASDAQ:PETX), Taro ... - KC Register
06/06/16 01:26 PMInotek Pharmaceuticals Corp. :ITEK-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 -
06/05/16 07:25 AMCan Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) Meet Analysts Expectations? - Stocks Daily
06/02/16 04:58 PMInotek Pharmaceuticals Corporation (ITEK) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News - Inotek Pharmaceuticals Corporation (ITEK) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Inotek Pharmaceuticals Corporation (ITEK). The latest reports which are currently in issue on Thursday 2nd of June state 0 analysts have a rating of “strong buy”, 0 ...and more »
05/26/16 12:24 PMNew Broker Ratings For Inotek Pharmaceuticals Corporation (ITEK) - FTSE News - New Broker Ratings For Inotek Pharmaceuticals Corporation (ITEK)FTSE News07/23/2015 – Inotek Pharmaceuticals Corporation had its “buy” rating reiterated by analysts at Nomura. They now have a USD 30 price target on the stock. The share price of Inotek Pharmaceuticals Corporation (ITEK) was down -2.26% during the last ...
05/26/16 08:00 AMinVentiv Health Elects David Southwell to Company's Board of Directors - [PR Newswire] - BURLINGTON, Mass., May 26, 2016 /PRNewswire/ -- inVentiv Health, Inc., a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market, today announced that David Southwell has been elected to its Board of Directors, effective immediately. Mr. Southwell will also serve as the Chairman of the Audit Committee. Mr. Southwell is currently President and Chief Executive officer of Inotek Pharmaceuticals Corporation (ITEK), a development-stage company focused on diseases of the eye.
05/11/16 07:38 AMInotek Pharmaceuticals Q1 Loss Widens - Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) reported a wider net loss for the first quarter. The company indicated it continued to enroll well and expect top-line data from the Phase 3 MATrX-1 trial in the fourth quarter. Inotek said its net loss was $10.1 million or a loss of $0.38 a share for the first quarter ended March, compared to a net loss of $1.5 million or a loss of $0.21 ...Full story available on Benzinga.com
05/11/16 06:22 AMInotek Pharmaceuticals Corporation Reports First Quarter 2016 Financial Results and Operational Highlights - [at noodls] - Inotek Pharmaceuticals Corporation Reports First Quarter 2016 Financial Results and Operational Highlights
05/11/16 06:07 AMInotek Pharmaceuticals reports 1Q loss -
05/10/16 06:23 AMWhy Inotek Pharmaceuticals Corporation Stock Rose 28.4% in April - A new chairperson and positive results from its lead candidate in glaucoma pushed this stock way up.
04/26/16 06:26 AMInotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting - [at noodls] - LEXINGTON, Mass.--(BUSINESS WIRE)--Apr. 26, 2016-- Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization ...
04/21/16 07:13 AMInotek Pharma Reports Publication of Phase 1 Data for Trabodenoson in JOPT - Inotek Pharmaceuticals Corporation (the "Company" or "Inotek") (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced the Journal of Ocular Pharmacology and Therapeutics (JOPT) has published the results from its Phase 1 dose-escalation trial in healthy adult volunteers of the Company's lead product candidate, trabodenoson. These results support the ongoing clinical development of trabodenoson as a novel treatment for glaucoma, and follow publication of the Phase 2 study in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT), announced on April 11, 2016. The research article, ...Full story available on Benzinga.com
04/21/16 06:10 AMInotek Pharmaceuticals Corporation Announces Publication of Phase 1 Data for Trabodenoson in Healthy Adult Volunteers in the Journal of Ocular Pharmacology and Therapeutics - [at noodls] - Trabodenoson Safe, Well Tolerated and Resulted in No Dose-related Ocular or Systemic Side Effects LEXINGTON, Mass.--(BUSINESS WIRE)--Apr. 21, 2016-- Inotek Pharmaceuticals Corporation (the 'Company' or ...
04/11/16 07:20 AMInotek Pharmaceuticals Announces the Journal of Ocular Pharmacology and Therapeutics has Published its Phase 2 Data for Trabodenoson in Patients with Glaucoma and Ocular Hypertension - [at noodls] - Trabodenoson Well Tolerated with Meaningful Reductions in Intraocular Pressure LEXINGTON, Mass.--(BUSINESS WIRE)--Apr. 11, 2016-- Inotek Pharmaceuticals Corporation (the 'Company' or 'Inotek') (NASDAQ:ITEK), ...
02/24/16 06:00 AMInotek Pharmaceuticals Announces Poster Presentation at the American Glaucoma Society’s 2016 Annual Meeting - [Business Wire] - Inotek Pharmaceuticals Corporation today announced that David S. Albers, Ph.D., Senior Director, Preclinical Research & Development of Inotek, will present a poster titled “Increased secretion of MMPs contributes to trabodenoson-induced changes in the conventional outflow facility” at the American Glaucoma Society’s 2016 Annual Meeting.
02/01/16 08:20 AMInotek Pharmaceuticals Announces Participation in Ophthalmology Panel at 18th Annual BIO CEO & Investor Conference on February 8th - [at noodls] - --(BUSINESS WIRE)--Feb. 1, 2016-- (NASDAQ:ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced ...
01/28/16 06:12 AMInotek Pharmaceuticals to Present at Glaucoma 360 New Horizons Forum - [at noodls] - www.inotekpharma.com. ... This is an abstract of the original noodl. To continue reading this document, click here for the original version.
01/12/16 06:42 AMINOTEK PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E -
01/12/16 06:20 AMInotek Pharmaceuticals Appoints Carsten Boess to Board of Directors - [at noodls] - --(BUSINESS WIRE)--Jan. 12, 2016-- (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced ...
12/16/15 08:28 AMInotek to Webcast First Research and Development Day - [at noodls] - - Event to Begin at , , 2015 - --(BUSINESS WIRE)--Dec. 16, 2015-- (NASDAQ: ITEK), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ...
12/10/15 04:23 AMInotek Pharmaceuticals Corporation Reports Third Quarter 2015 Financial Results and Operational Highlights - [at noodls] - -Initiated MATrX-1, the First Pivotal Phase 3 Clinical Trial of Trabodenoson, a Novel Treatment for Glaucoma- -Completed $79.2 Million Public Offering- -Expanded Management and Board of Directors with ...
12/10/15 04:23 AMInotek Pharmaceuticals to Present at the Piper Jaffray 27th Annual Healthcare Conference - [at noodls] - LEXINGTON, Mass.--(BUSINESS WIRE)--Nov. 24, 2015-- Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) (the 'Company' or 'Inotek'), a clinical stage biopharmaceutical company focused on the discovery, development ...
12/10/15 04:23 AMInotek to Host First Research and Development Day in New York City on December 17th, 2015 - [at noodls] - - Program to Feature Key Opinion Leaders in Ophthalmology - LEXINGTON, Mass.--(BUSINESS WIRE)--Nov. 25, 2015-- Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical stage biopharmaceutical company ...
12/08/15 12:17 PMINOTEK PHARMACEUTICALS CORP Financials -
12/08/15 10:15 AMPrimo Water Corporation (PRMW): Are Hedge Funds Right About This Stock? -
11/30/15 01:53 PMDo Hedge Funds Love POZEN Inc. (POZN)? -
11/12/15 07:16 AMInotek Pharmaceuticals reports 3Q loss -
11/12/15 07:01 AMINOTEK PHARMACEUTICALS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a -
11/05/15 07:00 AMInotek Pharmaceuticals to Present at the 2015 Ophthalmology Innovation Summit - [Business Wire] - Inotek Pharmaceuticals Corporation , a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that David P.
10/23/15 03:06 PMINOTEK PHARMACEUTICALS CORP Files SEC form 8-K/A, Change in Directors or Principal Officers -
10/16/15 07:32 AMINOTEK PHARMACEUTICALS CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
About Inotek Pharmaceuticals Corp

Inotek Pharmaceuticals Corp logoInotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye's natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye's trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ITEK
  • CUSIP:
Key Metrics:
  • Previous Close: $7.44
  • 50 Day Moving Average: $8.39
  • 200 Day Moving Average: $8.47
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $196.59M
  • Current Quarter EPS Consensus Estimate: $-1.62 EPS
Additional Links:
Inotek Pharmaceuticals Corp (NASDAQ:ITEK) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha